Cook Will Appeal Ruling Against Guidant Paclitaxel Stent Distribution
This article was originally published in The Gray Sheet
Executive Summary
Guidant has vowed to "define an organizational construct" that "allows for the commercialization of paclitaxel-eluting stents," following a June 13 court ruling against its Cook distribution agreement for access to the drug
You may also be interested in...
Centerpulse Rebounds 80% In Second Quarter As MDDI Index Drops 17%
Centerpulse stock surged 80.9% in the second quarter as final approval of a hip and knee class-action settlement dissipated the threat of bankruptcy, and the firm decided to divest its non-core businesses to focus on orthopedics. The issue closed at $16.55, up $7.40 for the three months
Centerpulse Rebounds 80% In Second Quarter As MDDI Index Drops 17%
Centerpulse stock surged 80.9% in the second quarter as final approval of a hip and knee class-action settlement dissipated the threat of bankruptcy, and the firm decided to divest its non-core businesses to focus on orthopedics. The issue closed at $16.55, up $7.40 for the three months
Post-Paclitaxel: Will Boston Scientific Cut Guidant Royalty Deal?
Boston Scientific's reluctance to grant Medtronic a license in 2001 in its dispute over rapid-exchange delivery technology may set a precedent for the next stage of the Boston Scientific/Guidant fight over drug-eluting stents